http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 05 Nov 2025 08:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html <div class="xn-content"> <p> <i>Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes.</i> </p> <p> http://www.streetinsider.com/PRNewswire/Satsuma+Pharmaceuticals+and+SNBL+Announce+Publication+of+Impression+of+Use+and+Satisfaction+with+STS101+%28Dihydroergotamine+Nasal+Powder+%28Atzumi%E2%84%A2%29%29+in+Headache/25558102.html Wed, 05 Nov 2025 08:00:00 -0500 2395 A.50114124 O.04957657 O.41848013 STSA http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Satsuma+Pharmaceuticals%2C+++++++++++++/21817730.html si-local-file:///var/storage/secattach/20230620/21817730.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Satsuma+Pharmaceuticals%2C+++++++++++++/21817730.html Tue, 20 Jun 2023 13:03:00 -0500 O.41848013 STSA http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Satsuma+Pharmaceuticals%2C+++++++++++++/21817730.html si-local-file:///var/storage/secattach/20230620/21817730.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Satsuma+Pharmaceuticals%2C+++++++++++++/21817730.html Tue, 20 Jun 2023 13:03:00 -0500 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html <p align="justify">DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2cimFWjHWtpxW9-dY2Y59dY5xzcvUCkhA_uoWsuUzaZcqGCvQIb6OP3YuECwq_-i8oZt0Jwmp7GeLRY25bG-U9wC0o0b7D2-a9FzSHpX8Dw=" rel="nofollow" target="_blank">Satsuma Pharmaceuticals, Inc.</a>, a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fu-fHcyPt11GvAr52l-lnOancXcuwSmC--rqoM-JKuloKqLHipf5iAuYwfL6t0ByphlnVXfJBXkO9bqZO2ZQcP87slsB6DSPe-fWBJ6lR3iZ5_LaoS-Vtfs9lRnCTS8gKpVJk_Zsqp7q0bWVEoTPgw==" rel="nofollow" target="_blank">Shin Nippon Biomedical Laboratories, Ltd.</a> (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s (AHS) 65th Annual Scientific Meeting. The 2023 meeting will http://www.streetinsider.com/Press+Releases/Satsuma+Pharmaceuticals+and+SNBL+Announce+Three+Abstracts+on+STS101+for+the+Acute+Treatment+of+Migraine+to+be+Presented+at+the+American+Headache+Society%E2%80%99s+65th+Annual+Scientific+Meeting/21802627.html Thu, 15 Jun 2023 08:00:00 -0500 2395 A.06822034 A.24633582 A.27689766 A.28618036 A.39238234 O.04870995 O.04957657 O.19958700 O.20026344 O.29366354 O.30503738 O.41848013 STSA